Compare
ANI Pharmaceuticals Inc vs Phibro Animal Health Corp vs Sinovac Biotech Ltd vs Perrigo Co PLC
| Latest fiscal year | ANI Pharmaceuticals Inc ANIP | Phibro Animal Health Corp PAHC | Sinovac Biotech Ltd SVA | Perrigo Co PLC PRGO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | $883.37M | $1.52B | $386.01M | $4.25B |
| Revenue growth (YoY) | +43.8% | +17.1% | +6.8% | -2.8% |
| Gross margin | n/a | 33.8% | 67.9% | 35.1% |
| Operating margin | 12.6% | 12.8% | -127.0% | -26.4% |
| Net margin | 8.9% | 6.6% | -51.5% | -33.5% |
| Net income | $78.34M | $99.72M | -$198.84M | -$1.43B |
| EPS (Diluted) | $3.32 | $2.43 | -$0.83 | -$10.29 |
| Operating cash flow | $185.22M | $68.95M | -$512.18M | $238.50M |
| Free cash flow | $171.39M | $9.87M | -$561.10M | $145.10M |
| Cash & equivalents | $285.58M | $61.42M | $488.25M | n/a |
| Total assets | $1.44B | $1.50B | $8.54B | $8.54B |
| Total liabilities | $899.65M | $1.12B | $2.15B | $5.60B |
| Shareholders' equity | $540.72M | $385.48M | $6.40B | $2.94B |
| Return on year-end equity | 14.5% | 25.9% | -3.1% | -48.6% |
| Shares outstanding | 22.49M | n/a | 71.86M | 137.60M |
Revenue, most recent five fiscal years
| Fiscal year | ANI Pharmaceuticals Inc | Phibro Animal Health Corp | Sinovac Biotech Ltd | Perrigo Co PLC |
|---|---|---|---|---|
| Latest | $883.37M Ended 2025-12-31 | $1.52B Ended 2026-06-30 | $386.01M Ended 2025-12-31 | $4.25B Ended 2025-12-31 |
| 1 year earlier | $614.38M Ended 2024-12-31 | $1.30B Ended 2025-06-30 | $361.37M Ended 2024-12-31 | $4.37B Ended 2024-12-31 |
| 2 years earlier | $486.82M Ended 2023-12-31 | $1.02B Ended 2024-06-30 | $470.17M Ended 2023-12-31 | $4.66B Ended 2023-12-31 |
| 3 years earlier | $316.38M Ended 2022-12-31 | $977.89M Ended 2023-06-30 | $1.47B Ended 2022-12-31 | $4.45B Ended 2022-12-31 |
| 4 years earlier | $216.14M Ended 2021-12-31 | $942.26M Ended 2022-06-30 | $19.37B Ended 2021-12-31 | $4.14B Ended 2021-12-31 |